Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Tofacitinib significantly improved skin and hair conditions without side effects.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Tofacitinib improved hair and nail conditions in a teen with alopecia areata.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Delonix polymeric nanoparticles with isotretinoin effectively treat acne by targeting hair follicles and reducing skin irritation.

Topical ruxolitinib cream may help treat frontal fibrosing alopecia.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Erlotinib can cause excessive eyelash growth.

Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

Baricitinib may effectively treat nail changes in alopecia areata.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

Topical tofacitinib shows promise as a future treatment for alopecia areata.